Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Hsi

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|February 10, 2010
OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemiaAnjali S Advani, Kathleen Lim, Sarah Gibson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2004
Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responsesChristine L O'Keefe, Magdalena Plasilova, Marcin Wlodarski, et al.
Leukemia Research|October 12, 2007
Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AMLAnjali S Advani, Cristina Rodriguez, Tao Jin, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 14, 2002
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disordersMichele Paessler, Plamen Kossev, Donald Tsai, et al.
European Journal of Haematology|June 26, 2012
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemiaAnna Brady, Sarah Gibson, Lisa Rybicki, et al.
Mayo Clinic Proceedings|July 14, 2006
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myelomaMohamad A Hussein, Rachid Baz, Gordan Srkalovic, et al.
Cancer|August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.
British Journal of Haematology|March 8, 2011
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)Anjali S Advani, Sarah Gibson, Elizabeth Douglas, et al.
British Journal of Haematology|February 7, 2019
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, et al.
Journal of the National Cancer Institute|July 7, 2016
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy ResponseYuhuan Zheng, Qiang Wang, Tianshu Li, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|February 10, 2010
OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemiaAnjali S Advani, Kathleen Lim, Sarah Gibson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2004
Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responsesChristine L O'Keefe, Magdalena Plasilova, Marcin Wlodarski, et al.
Leukemia Research|October 12, 2007
Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AMLAnjali S Advani, Cristina Rodriguez, Tao Jin, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 14, 2002
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disordersMichele Paessler, Plamen Kossev, Donald Tsai, et al.
European Journal of Haematology|June 26, 2012
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemiaAnna Brady, Sarah Gibson, Lisa Rybicki, et al.
Mayo Clinic Proceedings|July 14, 2006
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myelomaMohamad A Hussein, Rachid Baz, Gordan Srkalovic, et al.
Cancer|August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.
British Journal of Haematology|March 8, 2011
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)Anjali S Advani, Sarah Gibson, Elizabeth Douglas, et al.
British Journal of Haematology|February 7, 2019
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)Cara A Rosenbaum, Sin-Ho Jung, Brandelyn Pitcher, et al.
Journal of the National Cancer Institute|July 7, 2016
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy ResponseYuhuan Zheng, Qiang Wang, Tianshu Li, et al.
Pageof 4